Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Aquablation for LUTS due to BPH in men with localized prostate cancer.

The Canadian journal of urology·2026
Same author

Immune dysregulation in the prostates of C57BL/6<sup>Aire-/-</sup> mice mirrors that seen in human benign prostatic hyperplasia.

The Journal of pathology·2026
Same author

Editorial Comment.

The Journal of urology·2026
Same author

Symptoms and subtypes of patients with lower urinary tract dysfunction - insights from the Symptoms of Lower Urinary Tract Dysfunction Research Network.

Nature reviews. Urology·2026
Same author

DGAT1 Drives Racially Divergent Fibroblast Activation via ERK1/2-Dependent Tumorigenic Signaling in Prostate Cancer.

Cancer research communications·2026
Same author

Prostate Cancer, Genetic Susceptibility, and Risk of Chronic Non-Urological Complications.

The Prostate·2026

Related Experiment Video

Updated: Jun 18, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Established medical therapy for benign prostatic hyperplasia.

Gregory B Auffenberg1, Brian T Helfand, Kevin T McVary

  • 1Department of Urology, Feinberg School of Medicine, Northwestern University, 303 East Chicago Avenue, Tarry 16-703, Chicago, IL 60611-3008, USA.

The Urologic Clinics of North America
|November 28, 2009
PubMed
Summary

Benign prostatic hyperplasia (BPH) treatments include alpha-blockers, 5-alpha reductase inhibitors, and anti-muscarinic drugs. While phytotherapeutic supplements are popular, their safety and efficacy data remain limited for BPH management.

More Related Videos

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Related Experiment Videos

Last Updated: Jun 18, 2026

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).
06:04

Surgical Treatment for Benign Prostatic Hyperplasia: Holmium Laser Enucleation of the Prostate (HoLEP).

Published on: March 6, 2018

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing
05:25

Ultrasonography of the Adult Male Urinary Tract for Urinary Functional Testing

Published on: August 14, 2019

Area of Science:

  • Urology
  • Pharmacology

Background:

  • Benign prostatic hyperplasia (BPH) involves smooth muscle and epithelial proliferation in the prostate's transition zone.
  • BPH frequently leads to bothersome lower urinary tract symptoms (LUTS).

Purpose of the Study:

  • To review available clinical trial data for various medical therapies for benign prostatic hyperplasia.
  • To discuss the efficacy and safety of different pharmacologic and phytotherapeutic treatments for BPH.

Main Methods:

  • Review of clinical trial data for BPH therapies.
  • Discussion of pharmacologic mechanisms including alpha-receptor blockers, 5-alpha reductase inhibitors, and anti-muscarinic medications.
  • Evaluation of available evidence for phytotherapeutic supplements in BPH treatment.

Main Results:

  • Alpha-receptor blockers and 5-alpha reductase inhibitors are established first-line BPH therapies, effective alone or combined.
  • Anti-muscarinic medications show benefit for specific patient groups with storage LUTS due to bladder outlet obstruction.
  • Limited safety and efficacy data exist for many phytotherapeutic supplements used for BPH.

Conclusions:

  • Medical therapies, including alpha-blockers, 5-alpha reductase inhibitors, and anti-muscarinics, are evidence-based treatments for BPH.
  • Further research is needed to establish the safety and efficacy of phytotherapeutic supplements for benign prostatic hyperplasia.
  • Treatment choice for BPH should consider symptom profile and available clinical evidence.